Idera Pharmaceuticals Announces Issuance of a US Patent for Method of Inducing an Immune Response through Administration of Immu
04 Octobre 2006 - 3:25PM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the
issuance of US patent 7,115,579 (the �579 patent) for a method of
inducing an immune response via administration of certain compounds
that act through Toll-like Receptors (TLRs). The claims of this
patent, entitled �Modulation of oligonucleotide CpG-mediated immune
stimulation by positional modification of nucleosides� cover the
administration of selected immune modulatory oligonucleotides
through various routes. The compositions of the compounds claimed
in the �579 patent are covered in several of Idera�s patents and
patent applications, including EU1,278,761 and AU2001257366. �The
�579 patent is an important element in a succession of patents
recently issued to Idera that reinforce our intellectual property
portfolio in the Toll-like receptor field,� stated Sudhir Agrawal,
D. Phil., Idera�s Chief Executive Officer and Chief Scientific
Officer. �Idera�s drug discovery efforts based on DNA and RNA
chemistry have generated a very broad portfolio of compounds that
act as agonists or antagonists of TLRs.� Idera presently has over
150 patents and patent applications world-wide covering agonists of
TLR9, TLR8, and TLR7 and antagonists of TLR9. Idera�s entire
portfolio of DNA and RNA-based compounds has been designed through
in-house structure-activity relationship studies. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company with a pipeline of drug candidates to treat
cancer, and infectious, respiratory, and autoimmune diseases.
Idera�s proprietary drug candidates are designed to modulate TLRs,
the body�s first line of immune defense. Idera�s pioneering DNA
chemistry expertise enables it to identify drug candidates for
internal development and creates opportunities for multiple
collaborative alliances. Idera�s most advanced clinical candidate,
IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial
in oncology and in a Phase 1/2 chemotherapy combination trial in
oncology. Idera has selected a second TLR9 agonist, IMO-2125, as a
lead candidate for treating infectious diseases. Idera also is
collaborating with Novartis for the discovery, optimization,
development, and commercialization of additional TLR9 agonist
candidates for asthma and allergy. For more information, visit
www.iderapharma.com. Forward Looking Statements This press release
contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera�s
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera�s technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company�s
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company�s technology and prevent others from
infringing it; whether Idera�s cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera�s Quarterly Report on Form 10-Q filed on August 14, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements. Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced
the issuance of US patent 7,115,579 (the '579 patent) for a method
of inducing an immune response via administration of certain
compounds that act through Toll-like Receptors (TLRs). The claims
of this patent, entitled "Modulation of oligonucleotide
CpG-mediated immune stimulation by positional modification of
nucleosides" cover the administration of selected immune modulatory
oligonucleotides through various routes. The compositions of the
compounds claimed in the '579 patent are covered in several of
Idera's patents and patent applications, including EU1,278,761 and
AU2001257366. "The '579 patent is an important element in a
succession of patents recently issued to Idera that reinforce our
intellectual property portfolio in the Toll-like receptor field,"
stated Sudhir Agrawal, D. Phil., Idera's Chief Executive Officer
and Chief Scientific Officer. "Idera's drug discovery efforts based
on DNA and RNA chemistry have generated a very broad portfolio of
compounds that act as agonists or antagonists of TLRs." Idera
presently has over 150 patents and patent applications world-wide
covering agonists of TLR9, TLR8, and TLR7 and antagonists of TLR9.
Idera's entire portfolio of DNA and RNA-based compounds has been
designed through in-house structure-activity relationship studies.
About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug
discovery and development company with a pipeline of drug
candidates to treat cancer, and infectious, respiratory, and
autoimmune diseases. Idera's proprietary drug candidates are
designed to modulate TLRs, the body's first line of immune defense.
Idera's pioneering DNA chemistry expertise enables it to identify
drug candidates for internal development and creates opportunities
for multiple collaborative alliances. Idera's most advanced
clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company's technology and prevent others from
infringing it; whether Idera's cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera's Quarterly Report on Form 10-Q filed on August 14, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024